Bloomsbury Publishing

RNS Number: 8122 M Bloomsbury Publishing PLC 01 May 2018 The following amendments have been made to the' Acquisition of IBT Tauris& Co. Limited' announcement released on 1 May 2018 at 07.00 under RNS No 6564 M.. Bloomsbury Publishing Plc announces that it has today completed the acquisition of the entire issued share capital of IB Tauris& Co. Limited, the London-...

BloomsburyPublishing - Acquisition of IB Tauris & Co. Limited

RNS Number: 6564 M Bloomsbury Publishing PLC 01 May 2018 1 May 2018. Bloomsbury Publishing Plc announces that it has today completed the acquisition of the entire issued share capital of IBT Tauris& Co. Limited, the London- based academic publisher. The consideration was £5.8 million, of which £4.8 m was satisfied in cash at completion and up to £1.0 m will be...

BloomsburyPublishing - Acquisition of IBT Tauris & Co. Limited

Revenues increased 1% when adjusted for foreign exchange impact. U.S. revenues increased 1% to $2.8 billion in the quarter compared to the same period a year ago. When adjusted for foreign exchange impact, international revenues increased 1%. Gross margin as a percentage of revenue decreased from 74.3% to 69.5% in the quarter primarily due to product mix....

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Company today announced that the European Commission has approved an every four-week Opdivo monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced melanoma and previously treated renal cell carcinoma. The EC also approved a two-week Opdivo dosing option of 240 mg infused over 30 minutes...

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma

RNS Number: 3920 L Bloomsbury Publishing PLC 19 April 2018 19 April 2018. Bloomsbury is delighted to announce that Penny Scott-Bayfield will be joining the Board as Group Finance Director on 16th July 2018. She is an experienced Finance Director of a UK media company with specific experience of digital content, rapidly changing markets and growing new revenue...

BloomsburyPublishing - Board Appointment

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Opdivo to treat patients with small cell lung cancer whose disease has progressed after two or more prior lines of therapy. The FDA action date is August 16, 2018..

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review

Bristol-Myers Squibb Company today announced a worldwide collaboration with Janssen Pharmaceuticals, Inc. on a Factor XIa inhibitor program that includes the development and commercialization of Bristol-Myers Squibb’ s Factor XIa inhibitor, BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major...

Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

Bristol-Myers Squibb Company announced today two-year overall survival data from CheckMate -141, a Phase 3 open-label, randomized trial evaluating Opdivo compared with investigator’ s choice chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure on platinum-based therapy.

In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Bristol-Myers Squibb Company today announced that Opdivo 3 mg/kg plus Yervoy 1 mg/kg was approved by the U.S. Food and Drug Administration as the first Immuno-Oncology combination therapy for previously untreated patients with intermediate- and poor-risk advanced renal cell carcinoma. 1,2 In the Phase 3 CheckMate -214 clinical trial, the Opdivo+ Yervoy...

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Company today announced initial results from the pivotal Phase 3 study, CheckMate -227, evaluating the Opdivo 3 mg/kg plus low-dose Yervoy combination in first-line advanced non-small cell lung cancer patients with high tumor mutational burden≥ 10 mutations/megabase. In the study, the combination demonstrated a superior benefit...

Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB)

Findings will be presented on Monday, April 16 from 4:05 -4: 20 PM CDT during the Updates in Immuno-Oncology Trials session at the American Association for Cancer Research Annual Meeting 2018 in Chicago. Yi-Long Wu, principal investigator of CheckMate -078, commented,“ The prevalence of lung cancer in China continues to rise, and the disease remains a leading...

Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

Expands Illumina’ s Oncology Offerings for NextSeq™ 550 Dx. A Diagnostic Version of the Illumina TruSight™ Oncology 500 Assay Will Measure Potentially Predictive Genomic Biomarkers, Including Tumor Mutation Burden. NEW YORK& SAN DIEGO---- Bristol-Myers Squibb Company and Illumina, Inc. today announced a collaboration that will utilize Illumina’ s...

Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies

NEW YORK& CAMBRIDGE, Mass.---- Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute today announce a research collaboration to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. The Harvard Fibrosis Network brings together researchers across the schools...

Bristol-Myers Squibb and Harvard Announce New Fibrosis Research Collaboration

RNS Number: 4592 M Bloomsbury Publishing PLC 28 July 2017 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.. This form is required for disclosure of transactions under Article 19 of Regulation No 596/ 2014 of the European Parliament and of the Council of 16 April...

BloomsburyPublishing - Director/PDMR Shareholding

RNS Number: 0987 K Bloomsbury Publishing PLC 04 July 2017 Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons. All relevant boxes should be completed in block capital letters. This information is provided by RNS The company news service from the London Stock Exchange END DSHBXGDRXSGBGRS

RNS Number: 4510 I Bloomsbury Publishing PLC 19 June 2017 Annual Financial Report. Bloomsbury Publishing Plc confirms that the following documents are being sent to shareholders and, pursuant to Listing Rule 9.6. 1, are being submitted to the National Storage Mechanism and will be available for inspection at http://www.hemscott.com/nsm. do:.

BloomsburyPublishing - Annual Financial Report

RNS Number: 2430 I Bloomsbury Publishing PLC 16 June 2017 Bloomsbury Publishing Plc. Bloomsbury announces that, with effect from the close of business of the AGM on 18 July 2017, Sir Richard Lambert will join the Board as a non-executive Chairman for a term of four years. He is also a Member of Council for Chatham House, the Royal Institute of International Affairs....

RNS Number: 7259 F Bloomsbury Publishing PLC 19 May 2017 BLOCK LISTING SIX MONTHLY RETURN. Name of applicant: Bloomsbury Publishing Plc. Contact name: Michael Daykin- Group Company Secretary.

BloomsburyPublishing - 6 Month Blocklisting Return

RNS Number: 4811 F Bloomsbury Publishing PLC 18 May 2017 BLOOMSBURY PUBLISHING PLC. We are very pleased also at the impact of our trade publishing, having had two simultaneous number one bestsellers in February- Tom Kerridge's Dopamine Diet topping The Sunday Times non-fiction bestseller list and Neil Gaiman's Norse Mythology the fiction list.

Bloomsbury Publishing

BloomsburyPublishing - Acquisition of IB Tauris & Co. Limited

BloomsburyPublishing - Acquisition of IBT Tauris & Co. Limited

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Reports First Quarter Financial Results

Classification

Financials

Financials Data